key: cord-0707145-qedbfhpz
authors: Chang, De; Zhao, Peng; Zhang, Da-Wei; Dong, Jing-Hui; Xu, Zhe; Yang, Guang; Li, Bo-Yu; Liu, Hong-Xia; Li, Bo-An; Qin, Cheng-Feng; Peng, Xiao-Hua; Wang, Fu-Sheng; Xie, Li-Xin; Chen, Zhu; Dela Cruz, Charles S.; Sharma, Lokesh; Qin, En-Qiang
title: Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19
date: 2020-06-20
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2020.06.015
sha: 2408e2d5deccfc89321847a78431bc21e249a35d
doc_id: 707145
cord_uid: qedbfhpz

Abstract Background The clinical management of COVID-19 is dependent on understanding the underlying factors that contribute to the disease severity. In the absence of effective antiviral therapies, other host immunomodulatory therapies such as targeting inflammatory response are currently being used without clear evidence of their effectiveness. As inflammation is an essential component of host antiviral mechanisms, therapies targeting inflammation may adversely affect viral clearance and disease outcome. Objective To understand whether the persistent presence of the virus is a key determinant in the disease severity during COVID-19 and to determine if the viral reactivation in some patients is associated with infectious viral particles. Methods The data for patients were available including the onset of the disease, duration of viral persistence, measurements of inflammatory markers such as IL-6 and CRP, chest imaging, disease symptoms, and their durations among others. Follow up tests were performed to determine if the viral negative status persists after their recovery. Results Our data show that patients with persistent viral presence (>16 days) have more severe disease outcomes including extensive lung involvement and requirement of respiratory support. Two patients who died of COVID-19 were virus-positive at the time of their death. Four patients demonstrated virus-positive status on the follow-up tests and these patient samples were sent to viral culture facility where virus culture could not be established. Conclusion These data suggest that viral persistence is the key determining factor of the disease severity. Therapies that may impair the viral clearance may impair the host recovery from the COVID-19.

COVID-19 is the third and largest coronavirus mediated disease that emerged in the 21 st century. It has infected > 5 million people with more than 350,000 deaths (1) . The disease course of the COVID-19 varies significantly among individuals ranging from asymptomatic infection to severe disease leading to death (2) (3) (4) . The host and pathogen determinants are not known but possibly both exacerbated inflammatory host response, or direct virus-induced damage may lead to pathology. Excessive inflammation is often attributed to disease severity as well as mortality due to COVID-19 (5) (6) (7) . Surprisingly, the most susceptible population to remains to be the older individuals who are known to mount a poor inflammatory and immune response to a vast variety of viral infections as well as vaccines (8) . In this study, we aim to identify whether inflammatory response or impaired viral clearance leading to prolonged viral presence contribute toward disease severity.

Currently, there are no approved therapies for COVID-19 and initial approaches to enhance the viral clearance using ritonavir/lopinavir therapies failed to show any impact on viral clearance and the disease course (9) . The other antiviral therapies that are being used include remdesivir and chloroquine based on their in vitro activity against SARS-CoV-2 (10) . However, its antiviral efficacy and beneficial effects in COVID-19 remains to be known. However, a wide range of antiinflammatory therapies is currently being used in the clinical management of the COVID-19 despite a lack of knowledge regarding their beneficial effects on the disease (11, 12) .

Understanding whether the persistent viral presence or early inflammatory response guides the disease prognosis can provide critical clinical tools in the management of the disease. In this study, we demonstrate the role of persistent viral presence in contributing to the disease severity where the early inflammatory response was not related to the viral presence of adverse outcomes during the disease.

Re-emergence of the virus after the clinical recovery has also been a major concern and could pose a significant challenge in preventing the spread of the disease (13) . Currently, it is not clear what drives the re-emergence of the virus in some patients and whether these patients are infectious at this stage of the disease.

Source of the Data: Data were obtained from 69 patients admitted at the fifth medical center of Chinese PLA General Hospital from the early of January to the end of the March 2020 and discharged between Jan 28 and April 30 except three patients who remained hospitalized until April 20 th , 2020. Two patients died of COVID-19 and were excluded from the analysis.

Epidemiological history, the day of onset of symptoms were noted on their chart with other demographic information upon their presentation to the hospital. The viral qPCR was either performed at China Center for Disease Control (China CDC) or performed in the hospital laboratory where the presence of virus was confirmed during their admission and stay in the hospital every two days (2) . Routine measurements and laboratory tests were performed including markers of inflammation such as C-reactive Protein (CRP) and interleukin-6 (IL-6).

Measurement of D-dimer was performed in the blood samples. D-dimer is a fibrin derivative that is generated by its cleavage in the presence of plasmin (14) . D-dimer is a well-established marker of pulmonary embolism as well as deep vein thrombosis (14, 15) . Patients received standard of care as per guidelines by the Ministry of Public Health of China. Glucocorticoids were administered to the patients with progressive deterioration of oxygenation indicators, rapid progression of pathology in chest imaging, and overactivation of the inflammatory response (16) . All the patients were discharged from the hospital once their symptoms resolved, and they had two consecutive viral qPCR data showing the absence of the virus performed at Virus cultivation attempts were performed in Vero monolayers seeded in a 24-well plate.

Briefly, throat swabs from patients who were positive for SARS-CoV-2 by RT-qPCR were immersed, and serially diluted samples were inoculated into Vero monolayers. Cells were monitored daily for cytopathic effect (CPE) for five days, and viral replication in cell culture was detected by RT-qPCR or plaque assay. All experiments involving SARS-CoV-2 were performed in the BSL-3 facility at AMMS.

All the patients in this study were confirmed to have SARS-CoV-2 viral infection, detected by viral qPCR assay. The disease severity was classified as severe and nonsevere based on the clinical parameters as described before (17) . Two patients remained asymptomatic despite the presence of virus for 27 and 54 days respectively and they were included in the non-severe group.

The laboratory values were defined to be abnormal when they are out of their normal prescribed range. These ranges for various (4, 18) . The levels of cytokines and D-dimer were measured using chemiluminescence immunoassay assay (CLIA) kits (CRP from Beckman; IL-6 from Roche Diagnostics; and D-Dimer from Siemens Healthineers).

To understand the impact of viral persistence on disease severity, we divided the groups into two based on the days of viral persistence. The start day of the presence of viral was counted from the day of onset rather than the first positive test as the day of presentation to the hospital may be affected by various non-biological factors. The two deceased patients were excluded from the analysis as they were viral positive at their time of the death, and negative viral status was never reached. Our two groups were designated based on the viral clearance days where 16 days were set as cut off which divided our patient population in two almost even proportions (32 and 35 each group in short and long viral persistence groups, respectively).

Four of the 67 patients were found to be positive during the follow-up visits. Each patient was followed up at the 7 th , and 14 th day after discharge, if the patient virus test of throat swab turns to positive, it will be tested every 2-3 days until two consecutive viral qPCR showing negative. These tests were performed for every patient after their recovery and discharge from the hospital. These patients were further asked to be quarantined at their homes, and the throat swabs were sent to AMMS where these swabs were inoculated in Vero cells to measure cytopathy and viral load in the cell culture as a marker of the presence of a viable virus. If no cytopathy was observed, supernatants were collected and added to a new well and this process was repeated 3 times to ensure the detection of even low viral burden in these samples. The viral presence was detected by both cytopathy and viral qPCR and was deemed negative if none of these two parameters were positive. The culture success rate is more than 90% of the infected patients in the laboratory using this protocol from samples obtained during active disease. Patients were retested every 2-3 days again until the qPCR tests turned negative.

Statistical Analysis: Data were analyzed from 67 patients. The data between groups were compared using the chi-square test (for trend) or Fisher's exact test for categorical variables or t-test. Data were analyzed using GraphPad Prism (version 8.4.2).

Demographics and Clinical Characteristics of two Groups: The basic demographics of the patient population are demonstrated in Table 1 . Fever was the most common symptom present in 82% of the subjects and was not significantly different among the two groups. Similarly, other common symptoms like cough and fatigue were not significantly different among the two groups. In contrast, dyspnea was higher in the long-term viral persistent group compared to the short-term group (9% vs 29%, P = 0.06). Similarly, the use of ventilation or high flow oxygen or glucocorticoids were not different among the two groups.

Based on the disease severity, a significantly higher number of severe cases were noted in the long-term viral persistence group compared to the short-term viral presence group (12.5% in the short-term vs 40% in the long-term, P = 0.0139). Three of the total 14 severe cases in the long-term group were admitted to ICUs while no one from the short-term group was required ICU admission. Two of the patients with confirmed SARS-CoV-2 remained asymptomatic throughout their positive viral periods.

The two dead patients included a 79-year-old female and a 50-year-old male. Both of them reported hypertension as co-morbidity. Both had critical disease and were treated with glucocorticoids. The male and female patient died at day 17 and 28 post-hospital admission, respectively.

Imaging Evidence: To further evaluate the impact of viral persistence on lung injury, the CT scans were obtained, and the number of lobes that show abnormalities in each patient were quantified by two independent investigators. A significantly higher number of lobes were involved in patients having long-term viral presence compared to those who cleared the virus within 16 days post symptom onset ("2.938 ± 0.3505 in the short-term group vs "3.706 ± 0.2294 in the long-term group, Mean ± SEM) ( Fig. 1A & B) . Only one of the subjects in the long-term group had no evidence of pathological changes in any of the lobe while seven patients in the short-term group had no radiological evidence of the pathology. In contrast, all five lobes were involved in nine patients in the short-term group, but 12 patients had all five lobes of lung involvement in the long-term group. These data suggest an essential role of viral presence in causing lung pathology. Both the dead subjects demonstrated lung involvement by chest CT where involvement of all five lobes appeared in chest CT.

part of viral clearance in the lung. However, uncontrolled inflammation can lead to cytokine storm and septic shock with a potential grave prognosis. We analyzed the level of inflammatory markers in these patients and compared them among two groups based on the duration of viral persistence. Our data show that the percentage of patients showing elevated levels of IL-6 were similar in the two groups in the first week when data were available for a maximum number of patients ( Table 2 ). The majority of the patients had elevated values of IL-6 especially in the short-term group (60%) . Surprisingly, only 43% of the patients in the long-term viral persistence group had elevated levels of IL-6, although this did not reach statistical significance. Similarly, other markers of inflammation such as C-reactive proteins were not different among the two groups. However, levels of D-dimer, a marker that is associated with disease severity in COVID-19, was significantly elevated in a higher number of patients within the long-term group in both first (12.5% vs 37.14%, P = 0.0261) and second week (18.75% vs 60%, P = 0.001) of the hospital admission.

The blood counts for most of the patients were in the normal range including total white blood cell counts and neutrophils in the blood.

However, as described before a significant proportion of patients had lymphocytopenia, especially in those long-term viral persistent group (1 st week, 4/32 patients in the short-term and 10/35 patients in the long-term had lymphocytopenia, 2 nd week, 2/32 patients in the shortterm and 10/35 patients in the long-term had lymphocytopenia). CD4+ T cell counts were lower than normal in only 34% of the subjects in the short-term group compared to 63% in the longterm viral presence group within the first 10 days of the hospitalization (P = 0.028). Similar trends were observed for CD8+ T cells where only 12.5 % in the short-term group had lower CD8 T cell counts compared to 40% of the subjects had lower CD8 T cell counts in the long-term group (P = 0.0139). Similar trends were also observed for total T cells (Table 3) .

All the patients except three who are still in hospital were discharged after symptomatic recovery and confirming viral negative status (at least twice performed 24 hours apart). As part of the regular follow-up, patients that were discharged were followed up every week to obtain their throat swabs. Four of the swabs from these 64 patients turned positive at various time points after their confirmed negative status (Fig. 2) . The throat swabs were sent to the AMMS laboratory to test if the qPCR positive tests are indicative of the presence of a live pathogen. The swabs were plated on Vero cells to measure cytopathy and viral replication using qPCR of cell lysates after infection. We failed to detect any cytopathy or presence of viral replication in the infected cells. The time course of these patients is demonstrated in Fig. 2 . Individually, none of these patients had viral presence for more than 22 days, suggesting the re-emergence of viral positivity is not associated with impaired ability to clear the initial infection.

In this retrospective study, we demonstrate that the prolonged presence of the virus is a vital determinant of the disease severity and should be considered during therapeutic interventions.

Currently, there are no approved antiviral therapies for the COVID-19. However, various therapies that target inflammation are being used without clear evidence of their benefits (19) .

Inflammation including those mediated by interleukin-6 is essential for helping viral clearance and a decrease in overall inflammation may contribute to impaired viral clearance (20) . These data presented here warrant careful investigation of the impact of anti-inflammatory therapies such as those targeting IL-6, on viral clearance kinetics to ensure these therapies do not impair host anti-viral mechanisms.

Our data show that elevated inflammation measured by the circulating markers such as IL-6 or CRP was not a common feature of the patient population with long-term viral persistence.

Indeed, a trend toward a lower fraction of patients having elevated IL-6 was observed during the early course of the disease in the group with impaired viral clearance. In agreement with IL-6, a similar fraction of the population had elevated CRP in both the groups. Similarly, the number of total circulating WBC and neutrophils remained in the regular or lower range for most of the patients. These data suggest either lung-specific inflammatory response (21) that is not reflected in the circulation or SARS-CoV-2 mediated mechanisms that may actively suppress the host inflammatory response. However, the involvement of other inflammatory cytokines that are not measured here cannot be ruled out. It is also possible that the deleterious effects of inflammation are only observed during the late stage of the disease when the infectious viral burden is already significantly decreased. Long-term consequences of the elevated inflammatory response are recently reported in children where some children show inflammatory response manifested as Kawasaki disease (22) .

Elevation of D-dimer is known to be a major risk factor for the disease severity of COVID-19 (23) .

In our study, we demonstrate that patients with persistent viral presence show significantly elevated levels of D-dimer in both the first and second weeks of hospitalization, suggesting viral presence corroborates with previously reported disease severity markers. At the same time, the elevated level of D-dimer may suggest an involvement of the vascular system in mediating COVID-19 pathogenesis. Indeed, new disease phenotypes such as Kawasaki disease strongly suggest the role of vasculature inflammation in children as a chronic consequence after the viral clearance (22, 23) . Further studies are required to understand whether using antiinflammatory therapies such as targeting IL-6 can provide any potential benefit during Kawasaki disease.

It is unclear how the virus persists in the lung for such prolonged periods with manifestations of the disease. It seems plausible that the virus attacks host anti-viral immune response as evidenced by significant depletion of CD4+ and CD8+ cells in those with persistent viral presence. Our data support this hypothesis that lower levels of T lymphocytes, including CD4 and CD8+ cells, contribute to the lack of viral clearance, where these cells are actively targeted by the virus. Infected patients that can maintain sufficient levels of T cells can efficiently clear the virus and resolve the disease. Although, previous studies have reported that viral load is not associated with the disease, however, these viral loads were measured in upper airways rather than lung where major pathological events take place (24) . Further, recent studies have indicated the presence of angiotensin-converting enzyme 2 on T cells and the ability of SARS-CoV-2 to infect T cells (25) .

Host tolerance is the ability of the host to tolerate the virus without having significant pathological consequences to the host. Two of our patients had no clinical symptoms but were tested due to their known close contact with infected patients. These observations indicate that host tolerance is another major contributor in defining disease severity besides the host resistance (ability to clear the virus). Although only two patients in our cohort represented these populations with host tolerance sufficient to suppress any clinical symptoms, the precise fraction of this population can only be identified with extensive serological testing (26) .

Another critical point of discussion regards to the re-emergence of the virus in recovered patients. There has been significant concern regarding the re-emergence of the virus in patients that have recovered from the COVID-19 but become positive on the qPCR test. Four of our patients turned positive on their follow up visits after confirming viral negative status and resolution of symptoms. Despite our efforts to grow these viruses, we were unable to grow these viruses suggesting the possible presence of viral remnants rather than infective viral particles. As reported previously, the clinical features of these patients were not different among these patients (13) . Due to multiple positive qPCR tests, however, we believe that it was not due to error in the qPCR giving false-positive results.

In conclusion, our data demonstrate the urgent need for developing new antiviral therapies and at the same time, reconsider the role of therapies that may adversely affect the host's ability to clear the virus. We hope that these data will provide important clinical guidance to clinicians regarding the therapeutic approaches being used to treat COVID-19. Table 3 . Comparison of Blood Leukocyte Counts and Lymphocyte counts in two groups. P value between low and normal values between two groups are indicated by a , while p value between high and normal value between two groups are denoted by b . 

COVID-19) situation

Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection

Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside wuhan, china

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, china

Clinical features of patients infected with 2019 novel coronavirus in wuhan, china. The Lancet

COVID-19: Consider cytokine storm syndromes and immunosuppression. The Lancet

SARS-CoV-2: A storm is raging

Challenges for vaccination in the elderly

A trial of Lopinavir-Ritonavir in adults hospitalized with severe covid-19. 2020

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Tocilizumab treatment in COVID-19: A single center experience

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from china

Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation

Dimer for Long-Term Risk Prediction in Patients After Acute Coronary Syndrome: Jack of All Trades

D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: A systematic review

Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment

Interpretations of "diagnosis and treatment protocol for novel coronavirus pneumonia

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, china: A descriptive study

Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics

Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung

The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. medRxiv

An outbreak of severe kawasaki-like disease at the italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. The Lancet

Clinical features of patients infected with 2019 novel coronavirus in wuhan, china. The Lancet

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study

SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion

Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)